AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
![]() due to difficulty finding appropriately matched donors,” 2,3 said Tina Deignan, senior vice president, U.S. “ Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant, a potentially life-threatening complication that can pose a comparatively higher risk to racial and ethnic minority populations in the U.S. ![]() ![]() Food and Drug Administration (FDA) for the prophylaxis, or prevention, of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor (URD). Food and Drug Administration Approves Orencia ® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched or 1 Allele-Mismatched Unrelated Donorīristol Myers Squibb (NYSE:BMY) today announced that Orencia ® (abatacept) was approved by the U.S. ![]() Orencia is the first and only FDA-approved therapy to help prevent this serious complication that impacts between 30-70% of hematopoietic stem cell transplant recipients 1Īpproval marks fourth indication for Orencia, an established treatment across three rheumatic diseases 2 ![]()
0 Comments
Read More
Leave a Reply. |